drugset / Trial / NCT03051477
Trial of Mistletoe Extract in Patients With Advanced Solid Tumors
Phase 1
Completed
21 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Believe Big · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will seek to determine the safety and toxicity profile as well as the maximum tolerated dose of Helixor® M in patients with advanced solid tumors.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2021-01-29
- Completion
- 2022-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mistletoe extract | Unknown | — | Intravenous |